查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974469

蛋白質治療市場分析及預測（至2035年）：類型、產品類型、技術、應用、最終用戶、劑型、製程、安裝類型、設備

Protein Therapeutics Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Form, Process, Installation Type, Equipment
出版日期: | 出版商: Global Insight Services | 英文 494 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

蛋白質療法市場預計將從2024年的3,760億美元成長到2034年的7,408億美元，複合年成長率約為7%。蛋白質療法市場涵蓋用於治療多種疾病的生物來源蛋白質療法。該市場包括單株抗體、疫苗和肽激素，這些療法可提供高度特異性的標靶治療。慢性病發病率的上升和生物技術的進步正在推動市場成長，蛋白質工程和遞送系統的創新提高了治療效果和患者預後。監管支持和醫療保健支出的成長也進一步推動了市場擴張。

全球關稅和地緣政治緊張局勢正嚴重影響蛋白質療法市場，尤其是在東亞地區。日本和韓國正加大對生物製藥創新領域的策略性投資，以降低進口依賴並應對關稅的影響。中國在出口限制下，正著力提升生物製藥能力，以實現自給自足；而台灣則憑藉其先進的製造能力，力求在地緣政治脆弱性面前保持關鍵地位。在生物製藥和個人化醫療技術的推動下，全球蛋白質療法市場保持強勁成長。預計到2035年，在區域合作和生物相似藥創新的推動下，市場將持續成長。中東衝突透過加劇能源價格波動並可能擾亂生產和物流，間接影響該市場，凸顯了建立具有韌性的供應鏈策略的必要性。

市場區隔
類型 單株抗體、胰島素、紅血球生成素、干擾素、集落刺激因子、生長激素、凝血因子、酵素替代療法
產品 治療性蛋白質、疫苗、肽激素、血液因子
科技 重組DNA技術、融合瘤技術、基因改造技術、細胞培養
應用 癌症、代謝性疾病、血液疾病、自體免疫疾病、感染疾病、神經系統疾病
最終用戶 醫院、診所、研究機構、生物製藥公司
劑型 注射、口服劑、吸入劑、外用劑
流程 純化、配製和凍乾
安裝表格 內部、外包
裝置 生物反應器、層析法系統、過濾系統

由於生物技術的進步和慢性病發病率的上升，蛋白質療法市場正經歷強勁成長。單株抗體領域表現良好，這得益於其在治療多種疾病方面的特異性和療效。在該領域中，癌症和自體免疫疾病這兩個子領域表現尤為突出，反映了它們巨大的治療潛力。治療性蛋白質領域也呈現成長態勢，其中酵素和荷爾蒙在治療代謝和荷爾蒙失調方面發揮關鍵作用。

融合蛋白也日益受到關注，尤其是在腫瘤和感染疾病領域，它們能夠提高療效並減少副作用。受成本效益和多種生物製藥專利到期，生物相似藥的需求不斷成長，為市場參與者提供了盈利的機會。藥物遞送系統和個人化醫療的創新進一步推動了市場發展。在這個瞬息萬變的環境中，策略合作和研發投入對於抓住新機會、保持競爭優勢至關重要。

蛋白質療法市場呈現出市場佔有率多元化的特點，其價格環境受技術進步和策略聯盟的影響而呈現動態變化。近期新產品的推出為市場注入了活力，體現了企業對創新和滿足未被滿足的醫療需求的重視。主要企業正積極拓展產品系列，提升療效，並進軍細分市場。市場正經歷著向個人化醫療的轉變，這推動了對新型蛋白質療法的需求。北美繼續保持主導地位，而新興經濟體則提供了盈利的成長機會。

競爭基準分析顯示，市場競爭激烈，策略聯盟並存。各公司正利用最尖端科技取得競爭優勢。監管影響至關重要，北美和歐洲嚴格的監管準則塑造市場動態。法規環境既促進了創新，也保障了病人安全。新興市場正在適應全球標準，這既帶來了挑戰，也帶來了機會。在科技進步和醫療保健投資不斷成長的推動下，市場正處於成長軌道上。儘管高昂的研發成本和複雜的監管流程等挑戰依然存在，但突破性治療方法的潛力依然巨大。

主要趨勢和促進因素：

受生物技術進步和慢性病盛行率快速上升的推動，蛋白質療法市場正經歷強勁成長。生物製藥領域的創新正在推動新型蛋白質療法的研發，這些療法能夠提高治療效果並改善患者預後。與傳統藥物相比，這些療法具有更高的特異性和更少的副作用，因此正日益受到認可。

關鍵趨勢包括單株抗體的應用日益廣泛，其在癌症和自體免疫疾病的標靶治療中正獲得越來越多的定向。此外，由於專利到期以及對經濟高效替代療法的需求，生物相似藥的需求也在不斷成長。法規結構的完善進一步推動了這一趨勢，這些框架簡化了生物相似藥的核准，並加快了其市場准入。

此外，個人化醫療正成為關鍵驅動力，其中蛋白質療法在開發針對個人基因譜的客製化治療方法方面發揮著至關重要的作用。研發投入推動創新，而生技公司與學術機構的合作則加速了發現進程。對精準醫療和標靶治療的日益關注，為蛋白質療法領域創造了盈利的機遇，預計未來幾年將迎來顯著的市場擴張。

限制與挑戰：

蛋白質療法市場面臨許多重大限制和挑戰。其中一個突出的挑戰是高昂的研發和生產成本，加重了生產者和消費者的經濟負擔。監管障礙進一步阻礙了市場准入，嚴格的合規要求需要花費大量時間和資源。智慧財產權問題也構成障礙，專利到期加劇了生物相似藥的競爭。此外，蛋白質療法的複雜性需要複雜的儲存和分銷基礎設施，這帶來了物流方面的挑戰並增加了成本。最後，由於價格高昂和報銷問題，患者獲取藥物的機會有限，這阻礙了市場擴張，尤其是在發展中地區。這些因素共同限制了蛋白質療法市場的成長和廣泛應用。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 單株抗體
    • 胰島素
    • 促紅血球生成素
    • 干擾素
    • 集落刺激因子
    • 生長激素
    • 凝血因子
    • 酵素替代療法
  • 市場規模及預測：依產品分類
    • 治療性蛋白質
    • 疫苗
    • 肽激素
    • 血液因子
  • 市場規模及預測：依技術分類
    • 重組DNA技術
    • 融合瘤技術
    • 基因改造技術
    • 細胞培養
  • 市場規模及預測：依應用領域分類
    • 癌症
    • 代謝性疾病
    • 血液疾病
    • 自體免疫疾病
    • 感染疾病
    • 神經系統疾病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 醫療
    • 研究所
    • 生物製藥公司
  • 市場規模及預測：依類型
    • 注射
    • 口服
    • 吸入劑
    • 主題
  • 市場規模及預測：依製程分類
    • 純化
    • 配方
    • 冷凍乾燥
  • 市場規模及預測：依安裝類型分類
    • 內部開發
    • 外包
  • 市場規模及預測：依設備分類
    • 生物反應器
    • 層析法系統
    • 過濾系統

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Biocon
  • Sangamo Therapeutics
  • AbCellera Biologics
  • MacroGenics
  • Adaptimmune Therapeutics
  • BioNTech
  • CureVac
  • ImmunoGen
  • Kymab
  • Morphic Therapeutic
  • Pieris Pharmaceuticals
  • Sorrento Therapeutics
  • Argenx
  • Aptevo Therapeutics
  • Alector
  • Zymeworks
  • Allakos
  • Gritstone Oncology
  • Gossamer Bio
  • Harpoon Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS33198

Protein Therapeutics Market is anticipated to expand from $376.0 Billion in 2024 to $740.8 Billion by 2034, growing at a CAGR of approximately 7%. The Protein Therapeutics Market encompasses biologically-derived treatments using proteins to address various medical conditions. This market includes monoclonal antibodies, vaccines, and peptide hormones, offering targeted therapies with high specificity. The increasing prevalence of chronic diseases and advancements in biotechnology fuel market growth, with innovations in protein engineering and delivery systems enhancing therapeutic efficacy and patient outcomes. Regulatory support and rising healthcare expenditures further bolster market expansion.

Global tariffs and geopolitical tensions are profoundly influencing the Protein Therapeutics Market, particularly in East Asia. Japan and South Korea are strategically investing in biopharmaceutical innovation to mitigate reliance on imports and counter tariff impacts. China is accelerating its biopharma capabilities, focusing on self-sufficiency amidst export restrictions, while Taiwan leverages its advanced manufacturing to remain a pivotal player despite geopolitical vulnerabilities. The global protein therapeutics market is robust, driven by advancements in biologics and personalized medicine. By 2035, growth is anticipated to be sustained through regional collaborations and innovation in biosimilars. Middle East conflicts indirectly affect this market by exacerbating energy price volatility, which could disrupt manufacturing and logistics, highlighting the need for resilient supply chain strategies.

Market Segmentation
TypeMonoclonal Antibodies, Insulin, Erythropoietin, Interferons, Colony Stimulating Factors, Growth Hormones, Coagulation Factors, Enzyme Replacement
ProductTherapeutic Proteins, Vaccines, Peptide Hormones, Blood Factors
TechnologyRecombinant DNA Technology, Hybridoma Technology, Transgenic Technology, Cell Culture
ApplicationCancer, Metabolic Disorders, Blood Disorders, Autoimmune Diseases, Infectious Diseases, Neurological Disorders
End UserHospitals, Clinics, Research Institutes, Biopharmaceutical Companies
FormInjectable, Oral, Inhalable, Topical
ProcessPurification, Formulation, Lyophilization
Installation TypeIn-House, Outsourced
EquipmentBioreactors, Chromatography Systems, Filtration Systems

The Protein Therapeutics Market is experiencing robust growth, driven by advancements in biotechnology and increasing prevalence of chronic diseases. The monoclonal antibodies segment leads in performance, due to their specificity and effectiveness in treating various conditions. Within this segment, cancer and autoimmune diseases are top-performing sub-segments, reflecting their significant therapeutic potential. The therapeutic proteins segment follows closely, with enzymes and hormones being pivotal in addressing metabolic and hormonal disorders.

Fusion proteins are also gaining traction, particularly in oncology and infectious diseases, offering enhanced efficacy and reduced side effects. The demand for biosimilars is rising, driven by cost-effectiveness and the expiration of patents for several biologics, providing lucrative opportunities for market players. Innovations in drug delivery systems and personalized medicine are further propelling the market. Strategic collaborations and investments in R&D are crucial for capturing emerging opportunities and sustaining competitive advantage in this dynamic landscape.

The Protein Therapeutics Market is characterized by diverse market share, with a dynamic pricing landscape influenced by technological advancements and strategic alliances. Recent product launches have invigorated the market, reflecting innovation and a focus on addressing unmet medical needs. Key players are actively engaged in expanding their portfolios, enhancing therapeutic efficacy, and targeting niche segments. The market is witnessing a shift towards personalized medicine, driving demand for novel protein-based therapies. North America remains a dominant force, while emerging economies present lucrative opportunities for growth.

Competition benchmarking reveals a landscape marked by intense rivalry and strategic collaborations. Companies are leveraging cutting-edge technologies to gain competitive advantages. Regulatory influences play a pivotal role, with stringent guidelines in North America and Europe shaping market dynamics. The regulatory environment fosters innovation while ensuring patient safety. Emerging markets are adapting to global standards, presenting both challenges and opportunities. The market's trajectory is poised for growth, driven by scientific advancements and increasing healthcare investments. Challenges such as high development costs and complex regulatory pathways persist, yet the potential for groundbreaking therapies remains substantial.

Geographical Overview:

The protein therapeutics market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains at the forefront, driven by advanced healthcare infrastructure and significant R&D investments. The presence of key industry players further bolsters the region's market dominance. Europe follows closely, with strong government support and a focus on biopharmaceutical innovation enhancing market prospects. The region's emphasis on personalized medicine and biotechnology fuels growth.

In the Asia-Pacific region, the market is expanding rapidly due to increasing healthcare expenditures and a growing prevalence of chronic diseases. Countries like China and India are emerging as lucrative markets, owing to their large patient populations and rising demand for novel therapies. Latin America and the Middle East & Africa are also gaining traction. In Latin America, improvements in healthcare access and infrastructure drive market potential, while the Middle East & Africa benefit from increased investments in biotechnology and healthcare advancements.

Recent Developments:

The protein therapeutics market has experienced noteworthy developments over the past three months. Amgen announced a strategic collaboration with a leading biotech firm to enhance its protein engineering capabilities, aiming to accelerate drug discovery and development processes. This partnership is expected to significantly bolster Amgen\u2019s position in the protein therapeutics landscape.

In another significant move, Roche acquired a promising biotech company specializing in the development of novel protein-based therapies. This acquisition is set to enhance Roche\u2019s portfolio, providing access to innovative therapeutic candidates poised to address unmet medical needs across various therapeutic areas.

Regulatory advancements have also been prominent, with the FDA granting fast-track designation to a groundbreaking protein therapeutic developed by Biogen, aimed at treating a rare genetic disorder. This regulatory milestone underscores the potential of protein therapeutics in addressing complex medical conditions.

Meanwhile, Pfizer unveiled a cutting-edge protein therapeutic targeting a prevalent chronic disease, marking a significant addition to its existing product lineup. The launch is anticipated to drive substantial market growth, given the therapeutic\u2019s innovative mechanism of action.

Lastly, a joint venture between two pharmaceutical giants was announced, focusing on the development of next-generation protein therapeutics. This collaboration aims to leverage advanced technologies to create more effective and targeted therapies, highlighting the ongoing evolution and dynamism within the protein therapeutics market.

Key Trends and Drivers:

The Protein Therapeutics Market is experiencing robust growth, driven by advancements in biotechnology and a surge in chronic disease prevalence. Biopharmaceutical innovations are leading to the development of novel protein-based therapies, enhancing treatment efficacy and patient outcomes. These therapies are increasingly favored due to their specificity and reduced side effects compared to traditional pharmaceuticals.

A key trend is the expansion of monoclonal antibodies, which are gaining traction for their targeted action against cancer and autoimmune diseases. The market is also witnessing a rise in demand for biosimilars, driven by the expiration of patents and the need for cost-effective alternatives. This trend is further supported by regulatory frameworks that facilitate biosimilar approvals, expediting market entry.

Additionally, personalized medicine is emerging as a significant driver, with protein therapeutics playing a crucial role in tailoring treatments to individual genetic profiles. Investments in research and development are fostering innovation, while collaborations between biotech firms and academic institutions are accelerating discovery processes. The growing emphasis on precision medicine and targeted therapies is creating lucrative opportunities in the protein therapeutics landscape, promising substantial market expansion in the coming years.

Restraints and Challenges:

The protein therapeutics market is confronted with several significant restraints and challenges. One prominent challenge is the high cost of development and production, which increases the financial burden on manufacturers and consumers. Regulatory hurdles further complicate market entry, as stringent compliance requirements demand substantial time and resources. Intellectual property issues also present a barrier, with patent expirations leading to increased competition from biosimilars. Additionally, the complex nature of protein therapeutics necessitates advanced storage and distribution infrastructure, adding logistical difficulties and costs. Finally, limited patient access due to high prices and reimbursement issues restricts market expansion, particularly in developing regions. These factors collectively impede the growth and accessibility of the protein therapeutics market.

Key Companies:

Biocon, Sangamo Therapeutics, AbCellera Biologics, MacroGenics, Adaptimmune Therapeutics, BioNTech, CureVac, ImmunoGen, Kymab, Morphic Therapeutic, Pieris Pharmaceuticals, Sorrento Therapeutics, Argenx, Aptevo Therapeutics, Alector, Zymeworks, Allakos, Gritstone Oncology, Gossamer Bio, Harpoon Therapeutics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Installation Type
  • 2.9 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Insulin
    • 4.1.3 Erythropoietin
    • 4.1.4 Interferons
    • 4.1.5 Colony Stimulating Factors
    • 4.1.6 Growth Hormones
    • 4.1.7 Coagulation Factors
    • 4.1.8 Enzyme Replacement
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Proteins
    • 4.2.2 Vaccines
    • 4.2.3 Peptide Hormones
    • 4.2.4 Blood Factors
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Recombinant DNA Technology
    • 4.3.2 Hybridoma Technology
    • 4.3.3 Transgenic Technology
    • 4.3.4 Cell Culture
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Cancer
    • 4.4.2 Metabolic Disorders
    • 4.4.3 Blood Disorders
    • 4.4.4 Autoimmune Diseases
    • 4.4.5 Infectious Diseases
    • 4.4.6 Neurological Disorders
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Biopharmaceutical Companies
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Injectable
    • 4.6.2 Oral
    • 4.6.3 Inhalable
    • 4.6.4 Topical
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Purification
    • 4.7.2 Formulation
    • 4.7.3 Lyophilization
  • 4.8 Market Size & Forecast by Installation Type (2020-2035)
    • 4.8.1 In-House
    • 4.8.2 Outsourced
  • 4.9 Market Size & Forecast by Equipment (2020-2035)
    • 4.9.1 Bioreactors
    • 4.9.2 Chromatography Systems
    • 4.9.3 Filtration Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Form
      • 5.2.1.7 Process
      • 5.2.1.8 Installation Type
      • 5.2.1.9 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Form
      • 5.2.2.7 Process
      • 5.2.2.8 Installation Type
      • 5.2.2.9 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Form
      • 5.2.3.7 Process
      • 5.2.3.8 Installation Type
      • 5.2.3.9 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Form
      • 5.3.1.7 Process
      • 5.3.1.8 Installation Type
      • 5.3.1.9 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Form
      • 5.3.2.7 Process
      • 5.3.2.8 Installation Type
      • 5.3.2.9 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Form
      • 5.3.3.7 Process
      • 5.3.3.8 Installation Type
      • 5.3.3.9 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Form
      • 5.4.1.7 Process
      • 5.4.1.8 Installation Type
      • 5.4.1.9 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Form
      • 5.4.2.7 Process
      • 5.4.2.8 Installation Type
      • 5.4.2.9 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Form
      • 5.4.3.7 Process
      • 5.4.3.8 Installation Type
      • 5.4.3.9 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Form
      • 5.4.4.7 Process
      • 5.4.4.8 Installation Type
      • 5.4.4.9 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Form
      • 5.4.5.7 Process
      • 5.4.5.8 Installation Type
      • 5.4.5.9 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Form
      • 5.4.6.7 Process
      • 5.4.6.8 Installation Type
      • 5.4.6.9 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Form
      • 5.4.7.7 Process
      • 5.4.7.8 Installation Type
      • 5.4.7.9 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Form
      • 5.5.1.7 Process
      • 5.5.1.8 Installation Type
      • 5.5.1.9 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Form
      • 5.5.2.7 Process
      • 5.5.2.8 Installation Type
      • 5.5.2.9 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Form
      • 5.5.3.7 Process
      • 5.5.3.8 Installation Type
      • 5.5.3.9 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Form
      • 5.5.4.7 Process
      • 5.5.4.8 Installation Type
      • 5.5.4.9 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Form
      • 5.5.5.7 Process
      • 5.5.5.8 Installation Type
      • 5.5.5.9 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Form
      • 5.5.6.7 Process
      • 5.5.6.8 Installation Type
      • 5.5.6.9 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Form
      • 5.6.1.7 Process
      • 5.6.1.8 Installation Type
      • 5.6.1.9 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Form
      • 5.6.2.7 Process
      • 5.6.2.8 Installation Type
      • 5.6.2.9 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Form
      • 5.6.3.7 Process
      • 5.6.3.8 Installation Type
      • 5.6.3.9 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Form
      • 5.6.4.7 Process
      • 5.6.4.8 Installation Type
      • 5.6.4.9 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Form
      • 5.6.5.7 Process
      • 5.6.5.8 Installation Type
      • 5.6.5.9 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Biocon
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Sangamo Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 AbCellera Biologics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 MacroGenics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Adaptimmune Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 BioNTech
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 CureVac
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 ImmunoGen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Kymab
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Morphic Therapeutic
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Pieris Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Sorrento Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Argenx
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Aptevo Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Alector
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Zymeworks
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Allakos
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Gritstone Oncology
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Gossamer Bio
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Harpoon Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us